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Lanthanide conjugates as versatile instruments for
therapy and diagnostics
Claudine Herlana and Stefan Bräse *a,b
Lanthanides have demonstrated outstanding properties in many fields of research including biology and
medicinal chemistry. Their unique luminescence and magnetic properties make them the metals of
choice for next generation theranostics that efficiently combine the two central pillars of medicine –
diagnostics and therapy. Attached to targeting units, lanthanide complexes pave the way for real-time
imaging of drug uptake and distribution as well as specific regulation of subcellular processes with few
side effects. This enables individualized treatment options for severe diseases characterized by altered cell
expression. The highly diverse results achieved as well as insights into the challenges that research in this
area has to face in the upcoming years will be summarized in the present review.
Introduction
Modern theranostics require highly selective, multifunctional
materials that are easily detectable in the surrounding tissue
and capable of reliably transporting diverse cargoes. Due to
their unique properties, lanthanides are promising imaging
components of next generation diagnostics paving the way for
individualized therapeutics with few side effects. Their long-
lived luminescence in the visible to near-infrared range, large
Stokes and anti-Stokes shifts, outstanding photo-stability and
narrow emission regardless of the surrounding ligands make
lanthanides the metals of choice for in vivo imaging and real-
time tracking of drug uptake and distribution.1
Lanthanide luminescence results from Laporte-forbidden
f–f-transitions that result in long-lived excited states, but also
need organic receptors that transfer energy towards the metal
centre.2–5 This so-called antenna effect is crucial as the rare
earths are characterized by low absorption coefficients. Due to
versatile luminescence properties along the lanthanide row,6,7
a broad range of emission wavelengths is covered by choosing
an appropriate representative.8
Not only luminescence, but also magnetic resonance
imaging (MRI) is related to lanthanides.9,10 The most promi-
nent MRI contrast agents possessing clinical relevance are the
paramagnetic gadolinium(III) ion complexes. Unlimited pene-
tration depth and the absence of ionizing radiation are the
unique selling points of MRI-based in vivo imaging agents.9,11
As strong emitters that are easily distinguishable from back-
ground noise, rare earths fulfil various purposes in biological
and medicinal research. Besides their manifold diagnostic
applications, the lanthanides can function as therapeutics in
radiation or photodynamic therapy. Linked to targeting motifs
that transport the rare earths into desired tissues, the lantha-
nides are effective theranostics as consistently demonstrated
by their fascinating research outcomes.
Lanthanide conjugates in diagnostics
and therapy
Chemotherapeutics harm the entire organism due to severe
side effects since the reliable targeting of diseased cells is still
challenging. Several diseases are characterized by degenerated
cells possessing altered expression patterns of distinct surface
proteins. Conjugation to units that target these proteins paves
the way for cell-specific targeting which can be monitored by
means of lanthanides. This can be achieved, e.g., by using pep-
tidomimetics such as functionalized peptoids.12–16
To avoid the cytotoxicity of free metal ions, which is mainly
caused by binding to endogenous metalloproteins and sub-
sequent structure disruption, the metals are tightly complexed
with multidentate ligands.17–20 The most prominent chelators
are the macrocyclic 1,4,7,10-tetraazacyclododecane-1,4,7,10-
tetraacetate (DOTA) and its analogs (Fig. 1).21,22
Recently, the high specificity in vivo targeting of tumour
cells using a biotin-conjugated gadolinium(III)–DOTA (Gd(III)–
DOTA) complex has been reported (Fig. 2).23 Gd(III)–DOTA and
its analogs are commonly known to be efficient contrast
agents in clinical MRI and find use in many theranostic
applications.24–30 The described biotin-labelled Gd(III)–DOTA
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conjugate successfully delivered a highly potent cytostatic,
camptothecin, into cancer cells and allowed for real-time
imaging of its distribution and cellular uptake in vivo.
Administration of the pure anti-tumour drug resulted in severe
side effects due to the induced apoptosis of healthy cells. As
the prodrug is linked to the transporter-conjugate, the entire
organism is not harmed as internalization is realized only in
biotin-specific receptor overexpressing cancer cells. Once it
reaches the target, the intracellular environment triggers the
reductive cleavage of the incorporated disulfide bond and the
subsequent release of the cytostatic agent, revealing its thera-
peutic capability.
Lanthanides do not only serve as imaging agents for drug
tracking or diagnostic purposes,31 but also function as thera-
peutics on their own. Lutetium-177 is a medium-energy
β-emitter which permits monitoring via scintigraphy and con-
current tissue irradiation. Transporter-conjugates of Lu-177
complexes enable tailored radiotherapy with slight systemic
toxicity. In particular, peptides and related foldamers such as
peptoids that target certain receptors are linked to the radio-
nuclide, initiating their accumulation in malignant tissues.32
The method has been shown to be feasible for inoperable
neuroendocrine tumours that are efficiently targeted by
somatostatin and gastrin analogues.33–36 Clinical trials have
further revealed the promising effect of Lu-177 linked to ago-
nists of the prostate-specific membrane antigen. Targeting this
glycoprotein has shown to enable specific radionuclide




Although lanthanide conjugates work well in terms of speci-
ficity, their pharmacokinetic properties can be further
improved. Encapsulation into nanoparticles permits the
tuning of solubility, lowers systemic toxicity and promotes
transmembrane crossing.41 Surface decoration with targeting
units heightens the valency of interacting moieties and there-
fore the affinity of the entire particle.42 Due to these advan-
tages, a broad field of research deals with different kinds of
lanthanide-doped nanoparticles that can be easily functiona-
lized with distinct targeting motifs.43 However, their uptake is
restricted to certain cell types, which allows for tailored visual-
ization and therapy with few side effects.44
A common target for multifunctional nanophosphors is the
folate receptor, overexpressed in several human cancer cells
such as colon, lung, breast and ovarian.45,46 By masking nano-
particles with folic acid (Fig. 3), receptor-mediated uptake is
triggered, which exclusively transports the particles into cancer
cells while leaving the healthy ones untouched. This specificity
paves the way for targeted treatment of several diseases based
on cellular abnormalities. The principle mentioned is applied
to a variety of nanophosphors like nanocrystals47,48 or silica
nanoparticles.49–51
Among these nanocomposites, particles with unique
luminescence properties exist.52 Persistent luminescence
nanoparticles (PLNPs) are characterized by a luminescence
decay that lasts at least several seconds rendering background-
free detection in biological systems with a high signal-to-noise
ratio.53 The afterglow stems from the storage of excitation
energy by charged defects and subsequent slow release result-
ing in long-lived luminescence that can even last for days.41
Conjugation to folic acid permits tumour visualization clearly
distinguishable from the autofluorescence of surrounding
tissue.54,55
Another extensively investigated class of nanophosphors are
lanthanide-doped up-conversion nanoparticles (UCNPs). By
sequential absorption of photons or energy transfer, near-
infrared radiation is converted to visible light of higher energy,
which allows for minimized autofluorescence, low phototoxi-
city and sufficient tissue penetration while maintaining suit-
able luminescence. The properties of UCNPs as well as their
limitations from a physicochemical point of view have been
comprehensively discussed elsewhere.8 Folic acid conjugation
Fig. 1 The macrocyclic DOTA as a common leading structure for tight
lanthanide complexation.
Fig. 2 A biotin-conjugated (green) Gd(III)–DOTA complex (grey) that
efficiently delivered camptothecin (blue) into tumour cells.23
Fig. 3 Folic acid as a common targeting motif for several human
cancer types.
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triggers sole UCNP uptake in folate receptor overexpressing
cancer cell lines in vitro and in vivo.56–61
Besides folic acid, conjugation of nanophosphors to various
targeting units has been reported. Antibodies, functionalisable
glycoproteins, are known for their outstandingly high affinity
binding to certain targets ranging from metabolites to recep-
tors.62 Several working groups have benefited from their func-
tion when masking nanoparticles.63–67 Niu et al. visualized the
induced apoptosis of CD33 receptor overexpressing myeloid
leukemia cells caused by a humanized monoclonal antibody
conjugated to a lanthanide oxyfluoride nanoparticle. Apoptotic
events, induced by additionally conjugated peptide antagonists
of negative regulators of the tumour suppressor protein p53,
were triggered only in malignant cells, proving the antibody-
derived affinity.68 Antibody labelled nanophosphors were more-
over tested in vivo. Huang et al. reported the labelling of pan-
creatic cancer cell xenografts in mice using an antibody against
the cell surface proteoglycan glypican-1. The resulting nano-
probe showed efficient targeting without toxic side effects,
making it a promising candidate for clinical applications.69
Conjugation of specific peptides and other small bio-
molecules to nanocomposites has been extensively
studied.70–74 The cytokine interleukin-13 was chosen as a
reliable sensor for glioblastoma multiforme cells in xeno-
grafted mice. Lanthanide-doped metallofullerene-based inter-
leukin-13 nanoparticles paved the way for specific theranostic
treatment of this common malignant brain tumour which is
characterized by a median survival rate of merely one year.42,75
In the course of photodynamic therapy (PDT), lanthanides
serve as photosensitizers, which also makes them applicable as
composites for imaging purposes. Due to the heavy atom effect,
intersystem crossing from the singlet to triplet state is facilitated
after excitation of rare earths.76 In the triplet state, the reaction
with molecular oxygen is enabled generating a highly reactive
singlet oxygen species that causes severe disruption of the cellu-
lar environment, which efficiently leads to programmed cell-
death. A lot of research deals with lanthanide-doped UCNPs as
they are excitable in the deeper-tissue penetrating NIR
region.77–79 Recently, PDT-related apoptosis of certain cancer
cell lines after excitation of UCNPs with a low-power 980 nm
laser has been reported.80 Nevertheless, quantum yields of the
UCNPs as well as their targeting properties still have to be
improved. One approach towards the latter is the design of
smart nanoprobes that solely exhibit PDT activity in cancerous
tissue. Fan et al. stated that the high potential of this concept
lies in the luminescence and singlet oxygen generation by
cerium oxide based nanoparticles, so-called nanoceria, being
successfully turned on after matrix metalloproteinase-2 cata-
lysed cleavage of a certain peptide linker. The enzyme itself
serves as a biomarker for cancer diagnosis.81
Nanoceria derivatives do not only have applicability in PDT,
but also in the treatment of diseases that are related to
damage caused by singlet oxygen. Cerium nanoparticles are
characterised by charge deficiencies due to facile interconver-
sion between a trivalent and a tetravalent oxidation state and
subsequent surface oxygen vacancies. Redox-cycling allows for
scavenging reactive oxygen species which makes them thera-
peutic candidates against oxidative stress.82 Specific mitochon-
drial localization of triphenyl-phosphonium-modified nano-
ceria and significant suppression of Alzheimer’s disease
related neuronal death in transgenic mice were reported by
Kwon et al., confirming the reliability of this concept.83
Due to their manifold properties, lanthanide-doped nano-
particles come along with wide applicability in biology and
medicine. But although they are regarded as nontoxic, one has
to take into account that their metabolization is still not
understood in detail. Further research is required to clarify
their metabolic toxicity, avert their accumulation in liver and
the reticuloendothelial system and further improve their
pharmacokinetics.
Conclusions
Lanthanide conjugates with specific targeting ability have
been proved to show applicability as next generation therano-
stics. Their unique luminescence properties allow for back-
ground-free precise real-time imaging of drug uptake and dis-
tribution. Their outstanding suitability for MRI indicates their
usefulness in deep tissue in vivo imaging. The conjugation of
lanthanide complexes to targeting units as well as to medicinal
compounds paves the way for simultaneous diagnostics and
therapy. Incorporation of rare earths into nanoparticles can
enhance their pharmacokinetics, heighten multiplicity and
establish extraordinary properties. In certain types of therapy,
lanthanides can induce programmed cell death or neutralize
reactive oxygen species, offering innovative treatment options
for severe diseases.
Their comprehensive properties make the rare earths the
metals of choice for theranostic applications, sometimes
inspired by systems used in materials sciences.84–89 But
despite their manifold advantages, there are still challenges
that have to be overcome. Improvement of physicochemical
properties like quantum yield and efficiency has to be con-
sidered, while irradiation wavelengths and laser power need to
be optimized. This assists in lowering undesired side effects
such as tissue overheating and systemic toxicity caused by
high administered concentrations. The intrinsic toxicity of
metabolized lanthanide conjugates is still not fully clarified
and demands further efforts. Research on the rare earths
holds huge promise in biomedical applications and will conti-
nually reveal fascinating results in upcoming years.
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